{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-23-000405","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.470982+00:00","generated_at":"2026-06-08T13:40:51.423443+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Globus Medical Q3 revenue $383.6M (+51% YoY); raises FY revenue guidance to $1.55B","bullets":["GAAP net income $1.0M, diluted EPS $0.01; non-GAAP diluted EPS $0.57 (+14.7% YoY).","NuVasive merger closed Sept 1; combined results from that date drove 51% revenue increase.","Stand-alone Globus Medical net sales $281.2M (+10.7% YoY); U.S. +8.1%, International +25.5%.","Non-GAAP adjusted EBITDA $112.9M (29.4% of sales); free cash flow $29.0M.","FY 2023 revenue guidance raised to $1.55B (from $1.125B); non-GAAP EPS reaffirmed at $2.30."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-23-000405","json":"https://secwatch.observer/filing/0001562762-23-000405.json","markdown":"https://secwatch.observer/filing/0001562762-23-000405.md","text":"https://secwatch.observer/filing/0001562762-23-000405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276223000405/0001562762-23-000405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276223000405/gmed-20231107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:40:51.423443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ada86d858a3764bacd7a58883c668a6794984b1","claim":"GLOBUS MEDICAL INC reported the quarter ended September 30, 2023 results: revenue $383.6 million, net income $1.0 million, EPS $0.01.","evidence_excerpt":"merger with NuVasive, Inc. was completed on September 1, 2023 and results presented within include NuVasive, Inc. results from that closing date .  · Worldwide net sales were $ 383.6 million , an increase of 5 1.0 % . · GAAP net income for the quarter was $ 1.0 million · GAAP d iluted earnings per share (“ EPS ”) was $0. 0 1 and non-GAAP diluted EPS was $0. 57 ·","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276223000405/0001562762-23-000405-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$383.6 million"},{"label":"Net income","value":"$1.0 million"},{"label":"EPS","value":"$0.01"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e0a21be5654e425b3fdcfb73721c7e3c1bded4e7","claim":"GLOBUS MEDICAL INC reported full year fiscal 2023 results: revenue $1.55 billion, EPS $2.30. Guidance raised.","evidence_excerpt":"The Company today increased its full year fiscal 2023 revenue guidance to $1.55 billion, up from $1.125 billion, and reaffirmed non-GAAP fully diluted earnings per share guidance of $2.30.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276223000405/0001562762-23-000405-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year fiscal 2023"},{"label":"Revenue","value":"$1.55 billion"},{"label":"EPS","value":"$2.30"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}